BioStock: Elicera Therapeutics comes out of the gate running in Q2

For Swedish immuno-oncology company Elicera Therapeutics, the highlight of Q2 was going public and being listed on Nasdaq First North Growth Market, all while raking in more than 60 MSEK in a share issue. The events came as the company had reached new heights with its development pipeline and technology platform, iTANK.

Read the article at biostock.se:

https://www.biostock.se/en/2021/08/elicera-therapeutics-comes-out-of-the-gate-running-in-q2/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se